Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma

Background. The aim of this study was to assess the prognostic significance of the newly proposed 2015 World Health Organization (WHO) lung adenocarcinoma classification for patients undergoing resection for small (≤1 cm) lung adenocarcinoma. We also investigated whether lobectomy offers prognostic advantage over limited resection for this category of tumors. Methods. A retrospective study of resected pulmonary adenocarcinomas (n = 83) in sizes 1 cm or less was carried out in which comprehensive histologic subtyping was assessed according to the 2015 WHO classification on all consecutive patients who underwent lobectomy or limited resection between 1998 and 2012. Correlation between clinicopathologic parameters and the difference in recurrence between lobectomy and limited resection group was evaluated. Results. Our data show that the proposed 2015 WHO classification identifies histological subsets of small lung adenocarcinomas with significant differences in prognosis. No recurrence was noted for patients with adenocarcinoma in situ and minimally invasive adenocarcinoma. Invasive adenocarcinomas displayed high heterogeneity and the presence of micropapillary component of 5% or greater in adenocarcinomas was significantly related to lymph node involvement and recurrence ( P < .001). Stage IA patients who underwent limited resection had a higher risk of recurrence than did those treated by lobectomy ( P < .05). Conclusions. Application of the 2015 WHO classification identifies patients with adenocarcinoma in situ and minimally invasive adenocarcinoma had excellent prognosis. Micropapillary pattern was associated with high risk of lymph node metastasis and recurrence.

Download Full-text

DNA Methylation Changes in Atypical Adenomatous Hyperplasia, Adenocarcinoma In Situ, and Lung Adenocarcinoma

PLoS ONE ◽

10.1371/journal.pone.0021443 ◽

2011 ◽

Vol 6 (6) ◽

pp. e21443 ◽

Cited By ~ 70

Author(s):

Suhaida A. Selamat ◽

Janice S. Galler ◽

Amit D. Joshi ◽

M. Nicky Fyfe ◽

Mihaela Campan ◽

...

Keyword(s):

Dna Methylation ◽

Lung Adenocarcinoma ◽

Adenocarcinoma In Situ ◽

Atypical Adenomatous Hyperplasia ◽

Adenomatous Hyperplasia

Download Full-text

Assessment of invasion in lung adenocarcinoma classification, including adenocarcinoma in situ and minimally invasive adenocarcinoma

Modern Pathology ◽

10.1038/modpathol.2011.151 ◽

2012 ◽

Vol 25 (S1) ◽

pp. S1-S10 ◽

Cited By ~ 27

Author(s):

Alain C Borczuk

Keyword(s):

Minimally Invasive ◽

Lung Adenocarcinoma ◽

Adenocarcinoma In Situ ◽

Invasive Adenocarcinoma ◽

Minimally Invasive Adenocarcinoma

Download Full-text

KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma

Journal of Thoracic Oncology ◽

10.1097/jto.0b013e3181f8a164 ◽

2011 ◽

Vol 6 (1) ◽

pp. 220-222

Author(s):

Taylor M. Ortiz ◽

David W. Cohen ◽

Michael S. Kent ◽

Pasi A. Jänne ◽

Daniel B. Costa

Keyword(s):

Lung Adenocarcinoma ◽

Mutation Analysis ◽

Pulmonary Metastasis ◽

Kras Mutation ◽

Colon Adenocarcinoma ◽

Adenocarcinoma In Situ ◽

Primary Lung Adenocarcinoma

Download Full-text

Genomic and immune profiling of pre-invasive lung adenocarcinoma

Nature Communications ◽

10.1038/s41467-019-13460-3 ◽

2019 ◽

Vol 10 (1) ◽

Cited By ~ 15

Author(s):

Haiquan Chen ◽

Jian Carrot-Zhang ◽

Yue Zhao ◽

Haichuan Hu ◽

Samuel S. Freeman ◽

...

Keyword(s):

Minimally Invasive ◽

Lung Adenocarcinoma ◽

Copy Number ◽

Adenocarcinoma In Situ ◽

Copy Number Alterations ◽

Invasive Adenocarcinoma ◽

Minimally Invasive Adenocarcinoma ◽

Invasive Lung Adenocarcinoma ◽

Hla Loss

AbstractAdenocarcinoma in situ and minimally invasive adenocarcinoma are the pre-invasive forms of lung adenocarcinoma. The genomic and immune profiles of these lesions are poorly understood. Here we report exome and transcriptome sequencing of 98 lung adenocarcinoma precursor lesions and 99 invasive adenocarcinomas. We have identified EGFR, RBM10, BRAF, ERBB2, TP53, KRAS, MAP2K1 and MET as significantly mutated genes in the pre/minimally invasive group. Classes of genome alterations that increase in frequency during the progression to malignancy are revealed. These include mutations in TP53, arm-level copy number alterations, and HLA loss of heterozygosity. Immune infiltration is correlated with copy number alterations of chromosome arm 6p, suggesting a link between arm-level events and the tumor immune environment.

Download Full-text